bpc 157 human clinical trial randomized BPC-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded Multifunctionality and Possible Medical Application

In RA-FLS, an increase in glutamine transporters could support the role of glutamine as an alternate carbon source in the absence of glucose 45

present in ~40% of PV patients Plethora (facial redness/ruddy complexion) due to increased RBC mass and skin hyperemia Headache, dizziness, and visual disturbances from hyperviscosity and reduced cerebral blood flow Splenomegaly palpable in 7090% of PV patients from extramedullary hematopoiesis Thrombotic events (DVT, stroke, MI, Budd-Chiari syndrome) major complications from hyperviscosity Erythromelalgia burning pain/redness of hands and feet due to platelet-mediated microvascular occlusion Gout from elevated uric acid due to increased cell turnover Hypertension common comorbidity in PV Bleeding tendency paradoxically, despite elevated platelets, qualitative platelet dysfunction can cause GI bleeding Signs and symptoms that are routinely associated with a confirmed diagnosis of anemia or polycythemia (e.g., tachycardia, fatigue, pallor with anemia

Research Interest in BPC-157 + TB-500 Capsules BPC-157 + TB-500 capsules are part of a broader research peptide category that includes vials, sprays, capsules, and blended peptide formulations

Applications often focus on cardiovascular, neurological, and metabolic support

Compounding pharmacies do not add B12 randomly

Injections may be needed for severe deficiencies (only under medical supervision)